Pharma Focus Asia
KP - Choose our fully recyclable blister films

NRX-101 Represents New Class of Antidepressants to Decrease Suicidal Thoughts

NeuroRx's NRX-101, the first oral drug targeting suicidal  bipolar depression helps to treat severe bipolar depression with Acute Suicidal Ideation & Behavior (ASIB).

NRX-101 is used for treatment of Severe Bipolar Depression with Acute Suicidal Ideation & Behaviour after initial stabilisation with ketamine or other effective therapy.

NRX-101 (D-cycloserine/lurasidone fixed dose combination) is the first oral drug demonstrated in human volunteers to raise glutamine/glutamate (abbreviated Glx) in the anterior cingulate cortex of the brain on Magnetic Resonance Spectroscopy.

It is a patented, oral, fixed-dose combination of D-cycloserine (DCS), an NMDA antagonist, and lurasidone, which has 5-HT2a receptor antagonist activity.

DCS is shown to raise levels of two neurotransmitters: glutamate and glutamine (Glx). IT primarily raise serotonin levels in the brain.

NRX-101 may represent a new class of antidepressants with the potential to decrease suicidal thoughts, whereas serotonin-based antidepressants are associated with an increase in risk of suicide in certain vulnerable patient populations.

NRX-101 meets the extraordinary unmet medical need that confronts patients with Severe Bipolar Depression.

Patients with bipolar depression are at uniquely high risk for suicide, with more than 50% attempting suicide at some point and up to 20% succumbing to suicide.

NeuroRx is initiating a pivotal Phase 2b/3 clinical trial under the SPA comparing daily oral NRX-101 to standard therapy (lurasidone) in patients with Severe Bipolar Depression and Acute Suicidal Ideation following initial stabilization with ketamine.

Reduced levels of Glx have been reported in multiple studies of patients with depression and PTSD and increased Glx is correlated with improvement in depression as measured by rating scales.

Increased Glx has also been demonstrated with intravenous ketamine and ECT, but not with any known SSRI antidepressant.

NRX-101 is expected to allow treatment on an outpatient basis after an initial stabilization with NRX-100 (ketamine) in a clinical setting.

NRX-101 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024